Acumen Pharmaceuticals, Inc. presented positive topline results from the Phase 1 INTERCEPT-AD trial of ACU193, the first clinical-stage AβO targeting antibody therapy in early AD, at the Alzheimer’s Association International Conference 2023, taking place in Amsterdam and online from July 16-20, 2023.
